Condition
Esthesioneuroblastoma clinical trials and research
As of November 12, 2026, Find a Trial lists 5 Esthesioneuroblastoma clinical trials that are recruiting, at sites in 2 countries (most in United States (4), Spain (1)). By phase: Phase 1/2 (2), Phase 4 (1), Phase 1 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 2Countries
Newest Esthesioneuroblastoma clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Radiation plus tarlatamab for DLL3-expressing tumors | Phase 1/2 | Gilbert, Arizona and 2 other locations | Recruiting | Feb 7, 2025 |
| Combining Lutathera® and Olaparib for treating recurrent solid tumors in children and adolescents | Phase 1/2 | Boadilla del Monte, Madrid | Recruiting | Sep 23, 2024 |
| Targeted alpha therapy [212Pb]VMT-Alpha-NET for SSTR-positive metastatic or inoperable GI neuroendocrine, pheochromocytoma/paraganglioma, small cell lung, kidney, and head & neck cancers | Phase 1 | Bethesda, Maryland | Recruiting | Jun 28, 2024 |
| Understanding the natural history of olfactory neuroblastoma in patients | — | Bethesda, Maryland | Recruiting | Feb 16, 2021 |
| Using 68-Ga DOTATATE PET/MRI to Diagnose and Manage Certain Brain Tumors | Phase 4 | New York, New York | Recruiting | Sep 9, 2019 |
All recruiting trials (5)
-
Radiation plus tarlatamab for DLL3-expressing tumors
This trial will test whether giving tarlatamab together with standard palliative or consolidative radiation is safe for adults with DLL3-expressing or DLL3-prevalent tumors such as melanoma, medullary thyroid cancer, sinonasal undifferentiated carcinoma, esthesioneuroblastoma, and bladder cancer.
-
Combining Lutathera® and Olaparib for treating recurrent solid tumors in children and adolescents
This study is testing if combining Lutathera® with olaparib can help children and teenagers with hard-to-treat solid tumors that have certain receptors.
-
Targeted alpha therapy [212Pb]VMT-Alpha-NET for SSTR-positive metastatic or inoperable GI neuroendocrine, pheochromocytoma/paraganglioma, small cell lung, kidney, and head & neck cancers
This trial will try an experimental targeted alpha-particle drug called [212Pb]VMT-Alpha-NET in adults whose metastatic or inoperable tumors show somatostatin receptor (SSTR) expression.
-
Understanding the natural history of olfactory neuroblastoma in patients
This study is trying to learn more about olfactory neuroblastoma, a rare cancer in the nose, by gathering information on how it develops and affects patients to improve treatment options.
-
Using 68-Ga DOTATATE PET/MRI to Diagnose and Manage Certain Brain Tumors
This study is testing if a special type of imaging called 68Ga-DOTATATE PET/MRI can help doctors better diagnose and manage certain brain tumors, especially meningiomas, by telling the difference between tumor recurrence and changes after treatment.
Related topics
Quick answers
How many Esthesioneuroblastoma clinical trials are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 2 countries. The most sites are in United States (4 trials), Spain (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1/2: 2, Phase 4: 1, Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.